NOVEN ANNOUNCES COMMENCEMENT OF PHASE 2 STUDY OF INVESTIGATIONAL d-AMPHETAMINE TRANSDERMAL SYSTEM FOR ADHD October 2, 2012 − Miami, FL and New York, NY − Noven Pharmaceuticals, Inc., a whollyowned subsidiary of Hisam - Transdermal - Document - PDFSEARCH.IO

First Page	Meta Content
	NOVEN ANNOUNCES COMMENCEMENT OF PHASE 2 STUDY OF INVESTIGATIONAL d-AMPHETAMINE TRANSDERMAL SYSTEM FOR ADHD October 2, 2012 − Miami, FL and New York, NY − Noven Pharmaceuticals, Inc., a whollyowned subsidiary of Hisam Add to Reading List Document Date: 2013-06-27 13:51:08 Open Document File Size: 170,49 KB Share Result on Facebook

NOVEN ANNOUNCES COMMENCEMENT OF PHASE 2 STUDY OF INVESTIGATIONAL d-AMPHETAMINE TRANSDERMAL SYSTEM FOR ADHD October 2, 2012 − Miami, FL and New York, NY − Noven Pharmaceuticals, Inc., a whollyowned subsidiary of HisamAdd to Reading List